About Index Trending news
Analyze
Pricing
CareDx

CareDx

CareDx

AlloMap is a way to non-invasively test cardiac transplant patients for their risk of acute cellular rejection, graft failure, and death.

Elsewhere

Alexa global traffic share

Twitter followers

Latest funding Show all
Post-IPO debt
$25,000,000
Post-IPO equity
$22,170,000
Employees

Team size

50+
Locations
HQ
Headquarters
$25,000,000 Post-IPO debt
GlobeNewswire News Room

CareDx Closes New $25 Million Debt Facility